KCM
PTCT icon

Kennedy Capital Management’s PTC Therapeutics PTCT Stock Holding History

Kennedy Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,088
Closed -$205K – 637
2022
Q3 		$205K Buy
+4,088
New +$200K 0.01% 594

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kennedy Capital Management's PTCT Position: Q4 2022 in Review

Kennedy Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 4,088 shares — an estimated $205K sold.

Kennedy Capital Management first reported a position in PTCT in Q3 2022 and held it in 1 quarter. The position peaked at $205K in Q3 2022. 202 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

  • Kennedy Capital Management reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 4,088 PTC Therapeutics shares in Q4 2022, an estimated $205K.
  • Kennedy Capital Management first reported a position in PTC Therapeutics in Q3 2022 and held it in 1 quarter.
  • Kennedy Capital Management's PTC Therapeutics position peaked at $205K in Q3 2022.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on Kennedy Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.